| All participants . | |||
|---|---|---|---|
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 84 | 41 | 125 |
| TN05 (28) | 54 | 30 | 84 |
| TN08 (26) | 97 | 47 | 144 |
| TN09 (22) | 77 | 35 | 112 |
| TN14 (25) | 48 | 22 | 70 |
| TN19 (21) | 58 | 31 | 89 |
| Total | 418 | 206 | 624 |
| Subjects for C-peptide trajectory analysis . | |||
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 79 | 40 | 119 |
| TN05 (28) | 0 | 30 | 30 |
| TN08 (26) | 92 | 41 | 133 |
| TN09 (22) | 0 | 34 | 34 |
| TN14 (25) | 46 | 22 | 68 |
| TN19 (21) | 0 | 29 | 29 |
| Total | 217 | 196 | 413 |
| All participants . | |||
|---|---|---|---|
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 84 | 41 | 125 |
| TN05 (28) | 54 | 30 | 84 |
| TN08 (26) | 97 | 47 | 144 |
| TN09 (22) | 77 | 35 | 112 |
| TN14 (25) | 48 | 22 | 70 |
| TN19 (21) | 58 | 31 | 89 |
| Total | 418 | 206 | 624 |
| Subjects for C-peptide trajectory analysis . | |||
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 79 | 40 | 119 |
| TN05 (28) | 0 | 30 | 30 |
| TN08 (26) | 92 | 41 | 133 |
| TN09 (22) | 0 | 34 | 34 |
| TN14 (25) | 46 | 22 | 68 |
| TN19 (21) | 0 | 29 | 29 |
| Total | 217 | 196 | 413 |
| All participants . | |||
|---|---|---|---|
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 84 | 41 | 125 |
| TN05 (28) | 54 | 30 | 84 |
| TN08 (26) | 97 | 47 | 144 |
| TN09 (22) | 77 | 35 | 112 |
| TN14 (25) | 48 | 22 | 70 |
| TN19 (21) | 58 | 31 | 89 |
| Total | 418 | 206 | 624 |
| Subjects for C-peptide trajectory analysis . | |||
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 79 | 40 | 119 |
| TN05 (28) | 0 | 30 | 30 |
| TN08 (26) | 92 | 41 | 133 |
| TN09 (22) | 0 | 34 | 34 |
| TN14 (25) | 46 | 22 | 68 |
| TN19 (21) | 0 | 29 | 29 |
| Total | 217 | 196 | 413 |
| All participants . | |||
|---|---|---|---|
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 84 | 41 | 125 |
| TN05 (28) | 54 | 30 | 84 |
| TN08 (26) | 97 | 47 | 144 |
| TN09 (22) | 77 | 35 | 112 |
| TN14 (25) | 48 | 22 | 70 |
| TN19 (21) | 58 | 31 | 89 |
| Total | 418 | 206 | 624 |
| Subjects for C-peptide trajectory analysis . | |||
| Protocol . | Experimental . | Placebo . | Total . |
| TN02 (27) | 79 | 40 | 119 |
| TN05 (28) | 0 | 30 | 30 |
| TN08 (26) | 92 | 41 | 133 |
| TN09 (22) | 0 | 34 | 34 |
| TN14 (25) | 46 | 22 | 68 |
| TN19 (21) | 0 | 29 | 29 |
| Total | 217 | 196 | 413 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
